Fortress Biotech Inc. [NASDAQ: FBIO] traded at a high on 12/17/20, posting a 17.92 gain after which it closed the day’ session at $3.29. The company report on December 18, 2020 that ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – FBIO.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, 2020, inclusive (the “Class Period”), of the important January 26, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Fortress investors under the federal securities laws.
To join the Fortress class action, go to http://www.rosenlegal.com/cases-register-1997.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action.
The results of the trading session contributed to over 2969180 shares changing hands. Over the past one week, the price volatility of Fortress Biotech Inc. stands at 9.35% while the volatility over the past one month is 7.72%.
The market cap for FBIO stock reached $302.12 million, with 76.09 million shares outstanding and 71.30 million shares in the current float. Compared to the average trading volume of 1.13M shares, FBIO reached a trading volume of 2969180 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Fortress Biotech Inc. [FBIO]?
The Benchmark Company have made an estimate for Fortress Biotech Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 02, 2020. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on December 18, 2019, representing the official price target for Fortress Biotech Inc. stock. Previously, the target price had yet another raise to $10, while B. Riley FBR Inc. analysts kept a Buy rating on FBIO stock.
The Average True Range (ATR) for Fortress Biotech Inc. is set at 0.22, with the Price to Sales ratio for FBIO stock in the period of the last 12 months amounting to 7.03. The Price to Book ratio for the last quarter was 2.57.
How has FBIO stock performed recently?
Fortress Biotech Inc. [FBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 33.20. With this latest performance, FBIO shares gained by 23.68% in over the last four-week period, additionally plugging by 8.94% over the last 6 months – not to mention a rise of 51.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FBIO stock in for the last two-week period is set at 68.82, with the RSI for the last a single of trading hit 77.59, and the three-weeks RSI is set at 62.10 for Fortress Biotech Inc. [FBIO]. The present Moving Average for the last 50 days of trading for this stock 2.68, while it was recorded at 2.80 for the last single week of trading, and 2.78 for the last 200 days.
Fortress Biotech Inc. [FBIO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Fortress Biotech Inc. [FBIO] shares currently have an operating margin of -302.54 and a Gross Margin at +66.00. Fortress Biotech Inc.’s Net Margin is presently recorded at -109.09.
Return on Total Capital for FBIO is now -78.61, given the latest momentum, and Return on Invested Capital for the company is -42.14. Return on Equity for this stock declined to -284.75, with Return on Assets sitting at -21.75. When it comes to the capital structure of this company, Fortress Biotech Inc. [FBIO] has a Total Debt to Total Equity ratio set at 420.19. Additionally, FBIO Total Debt to Total Capital is recorded at 80.78, with Total Debt to Total Assets ending up at 48.65. Long-Term Debt to Equity for the company is recorded at 385.85, with the Long-Term Debt to Total Capital now at 74.17.
Reflecting on the efficiency of the workforce at the company, Fortress Biotech Inc. [FBIO] managed to generate an average of -$429,677 per employee. Receivables Turnover for the company is 3.33 with a Total Asset Turnover recorded at a value of 0.20.Fortress Biotech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.30 and a Current Ratio set at 6.40.
Earnings analysis for Fortress Biotech Inc. [FBIO]
With the latest financial reports released by the company, Fortress Biotech Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FBIO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Fortress Biotech Inc. go to 25.50%.
Insider trade positions for Fortress Biotech Inc. [FBIO]
There are presently around $102 million, or 33.70% of FBIO stock, in the hands of institutional investors. The top three institutional holders of FBIO stocks are: NANTAHALA CAPITAL MANAGEMENT, LLC with ownership of 8,224,938, which is approximately 85.877% of the company’s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 4,559,127 shares of the stock with an approximate value of $15.0 million in FBIO stocks shares; and OPALEYE MANAGEMENT INC., currently with $12.6 million in FBIO stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Fortress Biotech Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 45 institutional holders increased their position in Fortress Biotech Inc. [NASDAQ:FBIO] by around 9,298,673 shares. Additionally, 25 investors decreased positions by around 1,253,446 shares, while 18 investors held positions by with 20,333,761 shares. The mentioned changes placed institutional holdings at 30,885,880 shares, according to the latest SEC report filing. FBIO stock had 14 new institutional investments in for a total of 998,516 shares, while 10 institutional investors sold positions of 397,960 shares during the same period.